These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

513 related items for PubMed ID: 18678300

  • 1. Effects of adding prescription omega-3 acid ethyl esters to simvastatin (20 mg/day) on lipids and lipoprotein particles in men and women with mixed dyslipidemia.
    Maki KC, McKenney JM, Reeves MS, Lubin BC, Dicklin MR.
    Am J Cardiol; 2008 Aug 15; 102(4):429-33. PubMed ID: 18678300
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study.
    Davidson MH, Stein EA, Bays HE, Maki KC, Doyle RT, Shalwitz RA, Ballantyne CM, Ginsberg HN, COMBination of prescription Omega-3 with Simvastatin (COMBOS) Investigators.
    Clin Ther; 2007 Jul 15; 29(7):1354-67. PubMed ID: 17825687
    [Abstract] [Full Text] [Related]

  • 3. Baseline lipoprotein lipids and low-density lipoprotein cholesterol response to prescription omega-3 acid ethyl ester added to Simvastatin therapy.
    Maki KC, Dicklin MR, Davidson MH, Doyle RT, Ballantyne CM, COMBination of prescription Omega-3 with Simvastatin (COMBOS) Investigators.
    Am J Cardiol; 2010 May 15; 105(10):1409-12. PubMed ID: 20451686
    [Abstract] [Full Text] [Related]

  • 4. Effects of prescription omega-3-acid ethyl esters, coadministered with atorvastatin, on circulating levels of lipoprotein particles, apolipoprotein CIII, and lipoprotein-associated phospholipase A2 mass in men and women with mixed dyslipidemia.
    Maki KC, Bays HE, Dicklin MR, Johnson SL, Shabbout M.
    J Clin Lipidol; 2011 May 15; 5(6):483-92. PubMed ID: 22108152
    [Abstract] [Full Text] [Related]

  • 5. Effects of a new fish oil concentrate on plasma lipids and lipoproteins in patients with hypertriglyceridaemia.
    Mackness MI, Bhatnagar D, Durrington PN, Prais H, Haynes B, Morgan J, Borthwick L.
    Eur J Clin Nutr; 1994 Dec 15; 48(12):859-65. PubMed ID: 7889894
    [Abstract] [Full Text] [Related]

  • 6. Prescription omega-3 acid ethyl esters plus simvastatin 20 and 80 mg: effects in mixed dyslipidemia.
    Maki KC, Lubin BC, Reeves MS, Dicklin MR, Harris WS.
    J Clin Lipidol; 2009 Feb 15; 3(1):33-8. PubMed ID: 21291786
    [Abstract] [Full Text] [Related]

  • 7. Correlation of non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol with apolipoprotein B during simvastatin + fenofibrate therapy in patients with combined hyperlipidemia (a subanalysis of the SAFARI trial).
    Grundy SM, Vega GL, Tomassini JE, Tershakovec AM.
    Am J Cardiol; 2009 Aug 15; 104(4):548-53. PubMed ID: 19660610
    [Abstract] [Full Text] [Related]

  • 8. Effects of prescription omega-3-acid ethyl esters on fasting lipid profile in subjects with primary hypercholesterolemia.
    Maki KC, Lawless AL, Kelley KM, Dicklin MR, Kaden VN, Schild AL, Rains TM, Marshall JW.
    J Cardiovasc Pharmacol; 2011 Apr 15; 57(4):489-94. PubMed ID: 21297494
    [Abstract] [Full Text] [Related]

  • 9. Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial.
    Kastelein JJ, Maki KC, Susekov A, Ezhov M, Nordestgaard BG, Machielse BN, Kling D, Davidson MH.
    J Clin Lipidol; 2014 Apr 15; 8(1):94-106. PubMed ID: 24528690
    [Abstract] [Full Text] [Related]

  • 10. Long-term up to 24-month efficacy and safety of concomitant prescription omega-3-acid ethyl esters and simvastatin in hypertriglyceridemic patients.
    Bays HE, Maki KC, McKenney J, Snipes R, Meadowcroft A, Schroyer R, Doyle RT, Stein E.
    Curr Med Res Opin; 2010 Apr 15; 26(4):907-15. PubMed ID: 20156032
    [Abstract] [Full Text] [Related]

  • 11. Effects of prescription omega-3-acid ethyl esters on lipoprotein particle concentrations, apolipoproteins AI and CIII, and lipoprotein-associated phospholipase A(2) mass in statin-treated subjects with hypertriglyceridemia.
    Davidson MH, Maki KC, Bays H, Carter R, Ballantyne CM.
    J Clin Lipidol; 2009 Oct 15; 3(5):332-40. PubMed ID: 21291831
    [Abstract] [Full Text] [Related]

  • 12. The effect of prescription omega-3 fatty acids on body weight after 8 to 16 weeks of treatment for very high triglyceride levels.
    Bays HE, Maki KC, Doyle RT, Stein E.
    Postgrad Med; 2009 Sep 15; 121(5):145-50. PubMed ID: 19820283
    [Abstract] [Full Text] [Related]

  • 13. Effects of raloxifene and low-dose simvastatin coadministration on plasma lipids in postmenopausal women with primary hypercholesterolemia.
    Insull W, Davidson MH, Kulkarni PM, Siddhanti S, Ciaccia AV, Keech CA.
    Metabolism; 2005 Jul 15; 54(7):939-46. PubMed ID: 15988705
    [Abstract] [Full Text] [Related]

  • 14. [Efficacy and tolerability of simvastatin and omega-3 fatty acid combination in patients with coronary disease, hypercholesterolemia and hypertriglyceridemia].
    Tomei R, Rossi L, Carbonieri E, Franceschini L, Cemin C, Ghebremariam-Tesfau K, Zardini P.
    Cardiologia; 1993 Dec 15; 38(12):773-8. PubMed ID: 8200011
    [Abstract] [Full Text] [Related]

  • 15. Safety and efficacy of simvastatin in hypercholesterolemic patients undergoing chronic renal dialysis.
    Saltissi D, Morgan C, Rigby RJ, Westhuyzen J.
    Am J Kidney Dis; 2002 Feb 15; 39(2):283-90. PubMed ID: 11840368
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a phase 3, randomized, controlled study.
    Mohiuddin SM, Pepine CJ, Kelly MT, Buttler SM, Setze CM, Sleep DJ, Stolzenbach JC.
    Am Heart J; 2009 Jan 15; 157(1):195-203. PubMed ID: 19081418
    [Abstract] [Full Text] [Related]

  • 17. Effects of omega-3 carboxylic acids on lipoprotein particles and other cardiovascular risk markers in high-risk statin-treated patients with residual hypertriglyceridemia: a randomized, controlled, double-blind trial.
    Dunbar RL, Nicholls SJ, Maki KC, Roth EM, Orloff DG, Curcio D, Johnson J, Kling D, Davidson MH.
    Lipids Health Dis; 2015 Sep 02; 14():98. PubMed ID: 26328624
    [Abstract] [Full Text] [Related]

  • 18. Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study).
    Ballantyne CM, Davidson MH, McKenney J, Keller LH, Bajorunas DR, Karas RH.
    Am J Cardiol; 2008 May 15; 101(10):1428-36. PubMed ID: 18471454
    [Abstract] [Full Text] [Related]

  • 19. Comparison of the lipid-modifying efficacy and safety profiles of ezetimibe coadministered with simvastatin in older versus younger patients with primary hypercholesterolemia: a post Hoc analysis of subpopulations from three pooled clinical trials.
    Feldman T, Davidson M, Shah A, Maccubbin D, Meehan A, Zakson M, Tribble D, Veltri E, Mitchel Y.
    Clin Ther; 2006 Jun 15; 28(6):849-59. PubMed ID: 16860168
    [Abstract] [Full Text] [Related]

  • 20. Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: an exploratory analysis of archived samples using two commercially available techniques.
    Ose L, Reyes R, Johnson-Levonas AO, Sapre A, Tribble DL, Musliner T.
    Clin Ther; 2007 Nov 15; 29(11):2419-32. PubMed ID: 18158082
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.